Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with Artesunate, France, 2011–2013

Emerging Infectious Diseases

Volumn 21, Issue 5, 2015, Pages 804-812

  Jauréguiberry, Stéphane ^a,b,c   Thellier, Marc ^a,b,c   Ndour, Papa Alioune ^a   Ader, Flavie ^b   Roussel, Camille ^a   Sonneville, Romain ^d   Mayaux, Julien ^b   Matheron, Sophie ^d   Angoulvant, Adela ^b,e   Wyplosz, Benjamin ^b   Rapp, Christophe ^f   Pistone, Thierry ^g   Lebrun Vignes, Bénédicte ^b   Kendjo, Eric ^c   Danis, Martin ^a,b,c   Houzé, Sandrine ^d   Bricaire, François ^b   Mazier, Dominique ^a,b,c   Buffet, Pierre ^a,b,c   Caumes, Eric ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Center National de Référence du Paludisme Paris   (France)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f Hôpital d Instruction des Armées Begin   (France)

^g HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; BICARBONATE; BILIRUBIN; CREATININE; GLUCOSE; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; LACTIC ACID; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ACQUIRED HEMOLYTIC ANEMIA; ADULT; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FRANCE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALARIA; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PRURITUS; QUANTITATIVE ASSAY; RASH; TRAVEL; TREATMENT OUTCOME; ADOLESCENT; ANEMIA, HEMOLYTIC; COMPLICATION; HISTORY; MORTALITY; TRANSMISSION;

ADOLESCENT; ANEMIA, HEMOLYTIC; ANTIMALARIALS; ARTEMISININS; BLOOD TRANSFUSION; FEMALE; FRANCE; HISTORY, 21ST CENTURY; HUMANS; MALARIA; MALE; TRAVEL; TREATMENT OUTCOME;

EID: 84928027769     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2105.141171     Document Type: Article

References (37)

1. World Health Organization. The treatment of malaria, 2nd ed. Geneva: the Organization. 2010.
2. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–25. http://dx.doi.org/10.1016/S0140-6736(05)67176-0
3. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–57. http://dx.doi.org/10.1016/S0140-6736(10)61924-1
4. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Bierman WF, Clerinx J, van Veldhuizen CK, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012;11:102. http://dx.doi.org/10.1186/1475-2875-11-102
5. Mørch K, Strand Ø, Dunlop O, Berg A, Langeland N, Leiva RA, et al. Severe malaria and artesunate treatment, Norway. Emerg Infect Dis. 2008;14:1816–8. http://dx.doi.org/10.3201/eid1411.080636
6. Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard GD, Cramer JP. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J. 2012;11:169. http://dx.doi.org/10.1186/1475-2875-11-169
7. Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011;17:771–7. http://dx.doi.org/10.3201/eid1705.101229
8. Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6:CD005967.
9. Itoda I, Yasunami T, Kikuchi K, Yamaura H, Totsuka K, Yoshinaga K, et al. Severe falciparum malaria with prolonged hemolytic anemia after successful treatment with intravenous artesunate [in Japanese]. Kansenshogaku Zasshi. 2002;76:600–3. http://dx.doi.org/10.11150/kansenshogakuzasshi1970.76.600
10. Medicines for Malaria Venture. Experts Group Meeting on delayed anaemia following treatment with injectable artesunate [2015 Mar 7]. http://www.mmv.org/sites/default/files/uploads/docs/events/2013/InjectableArtesunateExpertGroupMeeting.pdf
11. Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013;12:241. http://dx.doi.org/10.1186/1475-2875-12-241
12. Centers for Disease Control and Prevention. Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria—worldwide, 2010–2012. MMWR Morb Mortal Wkly Rep. 2013;62:5–8.
13. Caramello P, Balbiano R, De Blasi T, Chiriotto M, Deagostini M, Calleri G. Severe malaria, artesunate and haemolysis. J Antimicrob Chemother. 2012;67:2053–4. http://dx.doi.org/10.1093/jac/dks139
14. Kano S. Artemisinin-based combination therapies and their introduction in Japan. J Infect Chemother. 2010;16:375–82. http://dx.doi.org/10.1007/s10156-010-0077-1
15. Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria—a double-center prospective study. J Infect Dis. 2014;209:1921–8. http://dx.doi.org/10.1093/infdis/jit841
16. World Health Organization, Global Malaria Programme. WHO information note on delayed haemolytic anaemia following treatment with artesunate: October 2013 [2015 Mar 7]. http://www.who.int/malaria/publications/atoz/who_note_delayed_haemolytic_anaemia_oct13.pdf?ua=1
17. Seringe E, Thellier M, Fontanet A, Legros F, Bouchaud O, Ancelle T, et al. Severe imported Plasmodium falciparum malaria, France, 1996–2003. Emerg Infect Dis. 2011;17:807–13. http://dx.doi.org/10.3201/eid1705.101527
18. Agence Nationale de Sécurité du Médicament. Protocole d’utilisation thérapeutique et de receuil d’informations Malacef® (artésunate) 60 mg, poudre et solvant pour solution injectable. Version 3; April 2013 [2015 Mar 7]. http://ansm.sante.fr/var/ansm_site/storage/original/application/01d138a64031bcf9f37fa2737308caa5.pdf
19. SPLIF. Management and prevention of imported Plasmodium falciparum malaria: recommendations for clinical practice 2007. (Revision 2007 of the 1999 consensus conference.) Short text. Med Mal Infect. 2008;38:54–67. http://dx.doi.org/10.1016/j.medmal.2007.11.007
20. World Health Organization, Communicable Diseases Cluster. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94 (Suppl 1):1–90. http://dx.doi.org/10.1016/S0035-9203(00)90300-6
21. Haut Conseil de la Santé Publique. Place de l’artésunate injectable dans le traitement du paludisme grave de l’adulte et de l’enfant. [2015 Mar 7]. http://www.hcsp.fr/explore.cgi/telecharger/hcspr20130201_palugraveartesunate.pdf
22. Dournon N, Buffet P, Caumes E, Clair B, Jaureguiberry S. Artesunate for severe acute Plasmodium falciparum infection in a patient with myasthenia gravis. Am J Trop Med Hyg. 2012;87:435–6. http://dx.doi.org/10.4269/ajtmh.2012.12-0114
23. Bruneel F, Tubach F, Corne P, Megarbane B, Mira JP, Peytel E, et al. Severe imported falciparum malaria: a cohort study in 400 critically ill adults. PLoS ONE. 2010;5:e13236. http://dx.doi.org/10.1371/journal.pone.0013236
24. Legros F, Bouchaud O, Ancelle T, Arnaud A, Cojean S, Le Bras J, et al. Risk factors for imported fatal Plasmodium falciparum malaria, France, 1996–2003. Emerg Infect Dis. 2007;13:883–8. http://dx.doi.org/10.3201/eid1306.060955
25. Eder M, Farne H, Cargill T, Abbara A, Davidson RN. Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre. Pathog Globl Health. 2012;106:181–7.
26. Corpolongo A, De Nardo P, Ghirga P, Gentilotti E, Bellagamba R, Tommasi C, et al. Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether–lumefantrine. Malar J. 2012;11:91. http://dx.doi.org/10.1186/1475-2875-11-91
27. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 1997;90:2037–40.
28. Buffet PA, Milon G, Brousse V, Correas JM, Dousset B, Couvelard A, et al. Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood. 2006;107:3745–52. http://dx.doi.org/10.1182/blood-2005-10-4094
29. Buffet PA, Safeukui I, Deplaine G, Brousse V, Prendki V, Thellier M, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood. 2011;117:381–92. http://dx.doi.org/10.1182/blood-2010-04-202911
30. Chotivanich K, Udomsangpetch R, Dondorp A, Williams T, Angus B, Simpson JA, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis. 2000;182:629–33.http://dx.doi.org/10.1086/315718
31. Jauréguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood. 2014;124:167–75. http://dx.doi.org/10.1182/blood-2014-02-555953
32. Hess KM, Goad JA, Arguin PM. Intravenous artesunate for the treatment of severe malaria. Ann Pharmacother. 2010;44:1250–8. http://dx.doi.org/10.1345/aph.1M732
33. Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars). 1998;58:50–3.
34. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med. 2008;358:1829–36. http://dx.doi.org/10.1056/NEJMct0709050
35. Maude RJ, Plewes K, Faiz MA, Hanson J, Charunwatthana P, Lee SJ, et al. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? Am J Trop Med Hyg. 2009;80:126–32.
36. Shanks GD. For severe malaria, artesunate is the answer. Lancet. 2010;376:1621–2. http://dx.doi.org/10.1016/S0140-6736(10)61928-9
37. World Health Organization. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J. 2012;11:424. http://dx.doi.org/10.1186/1475-2875-11-424